PA
LXRX icon

Pinnacle Associates’s Lexicon Pharmaceuticals LXRX Stock Holding History

Pinnacle Associates’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.3K Hold
29,015
– – ﹤0.01% 948
2025
Q4 		$33.4K Sell
29,015
-21,800
-43% -$29.9K ﹤0.01% 928
2025
Q3 		$68.6K Hold
50,815
– – ﹤0.01% 858
2025
Q2 		$48.1K Sell
50,815
-3,365
-6% -$2.18K ﹤0.01% 842
2025
Q1 		$25K Sell
54,180
-1,371,112
-96% -$865K ﹤0.01% 819
2024
Q4 		$1.05M Sell
1,425,292
-305,529
-18% -$368K 0.01% 478
2024
Q3 		$2.65M Buy
1,730,821
+14,990
+0.9% +$26.7K 0.05% 318
2024
Q2 		$2.88M Sell
1,715,831
-31,999
-2% -$57.4K 0.05% 307
2024
Q1 		$4.19M Buy
1,747,830
+17,009
+1% +$36.5K 0.07% 266
2023
Q4 		$2.65M Sell
1,730,821
-182,048
-10% -$216K 0.04% 322
2023
Q3 		$2.09M Sell
1,912,869
-80,758
-4% -$142K 0.04% 349
2023
Q2 		$4.57M Buy
1,993,627
+53,403
+3% +$142K 0.08% 243
2023
Q1 		$4.71M Buy
1,940,224
+7,447
+0.4% +$17.1K 0.1% 212
2022
Q4 		$3.69M Sell
1,932,777
-98,430
-5% -$209K 0.08% 229
2022
Q3 		$4.88M Sell
2,031,207
-56,256
-3% -$156K 0.11% 200
2022
Q2 		$3.88M Sell
2,087,463
-6,831
-0.3% -$13K 0.08% 228
2022
Q1 		$4.38M Sell
2,094,294
-33,368
-2% -$92.5K 0.08% 238
2021
Q4 		$8.38M Buy
2,127,662
+30,015
+1% +$146K 0.14% 164
2021
Q3 		$10.1M Sell
2,097,647
-93,135
-4% -$382K 0.19% 139
2021
Q2 		$10.1M Buy
2,190,782
+23,610
+1% +$114K 0.18% 142
2021
Q1 		$12.7M Buy
2,167,172
+314,790
+17% +$2.18M 0.24% 118
2020
Q4 		$6.33M Buy
1,852,382
+1,505,122
+433% +$2.87M 0.13% 174
2020
Q3 		$500K Sell
347,260
-11,250
-3% -$20K 0.01% 487
2020
Q2 		$715K Buy
358,510
+2,165
+0.6% +$4.24K 0.02% 428
2020
Q1 		$695K Sell
356,345
-43,029
-11% -$128K 0.02% 398
2019
Q4 		$1.66M Sell
399,374
-71,975
-15% -$277K 0.04% 329
2019
Q3 		$1.42M Sell
471,349
-39,485
-8% -$122K 0.03% 349
2019
Q2 		$3.21M Sell
510,834
-39,715
-7% -$238K 0.08% 251
2019
Q1 		$3.06M Buy
550,549
+9,615
+2% +$58.4K 0.07% 255
2018
Q4 		$3.59M Sell
540,934
-37,785
-7% -$306K 0.09% 232
2018
Q3 		$6.17M Sell
578,719
-96,106
-14% -$1.1M 0.13% 185
2018
Q2 		$8.1M Sell
674,825
-115,860
-15% -$1.19M 0.17% 160
2018
Q1 		$6.78M Sell
790,685
-63,490
-7% -$587K 0.13% 179
2017
Q4 		$8.44M Sell
854,175
-42,870
-5% -$445K 0.16% 158
2017
Q3 		$11M Buy
897,045
+182,215
+25% +$2.69M 0.2% 120
2017
Q2 		$11.8M Buy
+714,830
New +$11.1M 0.23% 112

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Pinnacle Associates's LXRX Position: Q1 2026 in Review

Pinnacle Associates held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2026 at 29,015 shares worth $45.3K. The position accounts for ﹤0.01% of the portfolio, ranked #948.

Pinnacle Associates first reported a position in LXRX in Q2 2017 and has held it in 36 quarters since. The position peaked at $12.7M in Q1 2021. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Pinnacle Associates held 29,015 shares of Lexicon Pharmaceuticals worth $45.3K as of Q1 2026.
  • Pinnacle Associates left its Lexicon Pharmaceuticals share count unchanged in Q1 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Pinnacle Associates's portfolio in Q1 2026, its #948 holding.
  • Pinnacle Associates first reported a position in Lexicon Pharmaceuticals in Q2 2017 and has held it in 36 quarters since.
  • Pinnacle Associates's Lexicon Pharmaceuticals position peaked at $12.7M in Q1 2021.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.